Last year, top researchers in Alzheimer's Disease treatments published a scientific journal article describing how a new drug can slow the cognitive decline of Alzheimer's patients by 36%, and by nearly 50% for people with a particularI am interested in writing what others have not written. For instance, I plan on detailing how the Biden solar import duty (tax) policy is the greatest blockade in the growth of clean energy on our planet. My particular areas of interest include clean energy, Alzheimer's drugs ...

I continue to reassess the mechanisms of action of blarcamesine and the causes of Alzheimer’s disease itself based on Anavex’s (NASDAQ: AVXL ) long-term open label trial results . Blarcamesine appears to perform no better than Aricept forRetired history instructor. Alzheimer's disease researcher for the past two decades.My goal is to give investors solid advice based on the mechanisms of action of Alzheimer's drugs. This advice is informed by a background in biology (conservation, ecology, evolution, enviro ...

H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ and H.C. Wainwright 6th Annual Neuro Perspectives ConferenceNEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-37606 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) (State or other jurisdiction o ...

Anavex Life Sciences (AVXL) Q2 2025 Earnings Call May 13, 2025 08:30 AM ET Speaker0 For today's call. At this time, all participants are in a listen only mode. Later, will conduct a question and answer session. And during this session, if you would like to ask a question, please use the q and a box or raise your hand. Please note this conference is being recorded, and the call will be available for replay on Anavex's website at www.Anavex.com. With us today is doctor Christopher Missling, president and chie ...

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today reported financial results for its second quarter of ...

Core Viewpoint - Anavex Life Sciences Corp. is set to release its financial results for the second fiscal quarter on May 13, 2025, and will host a conference call to discuss these results and the company's growth strategy [1][2]. Company Overview - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for various CNS disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, and Rett syndrome [1][4]. - The company's lead drug candidate, ANAVEX2-73 (blarcamesine), has completed multiple clinical trials for Alzheimer's disease and is also being studied for Parkinson's disease dementia and Rett syndrome [4]. - ANAVEX2-73 is designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, with preclinical studies indicating its potential to halt or reverse Alzheimer's disease progression [4]. - Another promising drug candidate, ANAVEX3-71, targets SIGMAR1 and M1 muscarinic receptors and has shown beneficial effects in preclinical trials related to Alzheimer's disease [4]. Conference Call Details - The conference call will take place on May 13, 2025, at 8:30 am ET, and will include a question-and-answer session following management's remarks [2][3]. - Participants can access the call via a live webcast on Anavex's website or by dialing a specific number for U.S. participants [3].

Core Insights - Anavex Life Sciences Corp. has successfully completed enrollment for its Phase 2 clinical study of ANAVEX3-71, targeting schizophrenia, with a total of 71 participants [2][3][4] - The study consists of two parts: Part A with 16 participants focusing on multiple ascending doses, and Part B with 55 participants aimed at providing comprehensive clinical and biomarker data [3][4] - Top-line data from the study is expected to be reported in the second half of 2025 [5] Company Overview - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing treatments for various CNS disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia [2][7] - The lead drug candidate, ANAVEX2-73, has shown promise in multiple clinical trials for Alzheimer's disease and other CNS disorders [7][8] - ANAVEX3-71 is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator, which may address all symptom domains of schizophrenia without the side effects associated with standard antipsychotics [4][8] Industry Context - Schizophrenia affects nearly 24 million people globally, with significant unmet medical needs due to limitations of current treatments [6] - Approximately 34% of individuals with schizophrenia do not respond to existing therapies, and 50-60% experience only partial improvement or unacceptable side effects [6]

NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at The Citizens Life Sciences Conference, taking place in New York, NY, from M ...

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Professor Dr. Audrey Gabelle, MD, PhD, a specialist of predictive, personalized m ...